Ivermectin

VENTURA, Calif., Dec. 7, 2023 /PRNewswire/ -- Last month, ProgenaBiome™, a genetic research lab dedicated to studying and understanding the the microbiome, received yet another presidential award from the American College of Gastroenterology (ACG) at the ACG Annual Scientific Meeting in Vancouver. This marks their fourth year of attendance at the conference and third consecutive year of presidential-level recognition for research on the microbiome. Continue Reading Photo courtesy of Dr. Sabine Hazan from the ACG Conference in Vancouver, Canada. Dr. Sabine Hazan with ProgenaBiome's submitted abstracts at the 2023 ACG Conference in Vancouver, Canada. The ACG conference brings GI physicians and researchers from around the world to discuss the latest clinical information in gastroenterology and hepatology. According to ACG, each year less than 5% of accepted abstracts are awarded the presidential distinction for "high quality, novel, unique, and interesting research." ProgenaBiome was given the award for their research on commercial Probiotic products. Their groundbreaking findings indicated significant discrepancies between probiotic food label claims and their contents. More specifically, only five out of 25 tested commercially available products with label-promised Bifidobacteria – an organism essential for a healthy microbiome – truly contained the bacteria. Dr. Sabine Hazan, world-renowned gastroenterologist, and founder of ProgenaBiome, explained that this research raises an important, though disheartening, fact about the commercial health industry. "The abstract on probiotics shows the need for quality testing of health products by an independent party. But more importantly, it shows that there is marketing and influencing that exists to mislead consumers," said Hazan. In addition to this research, ProgenaBiome submitted 3 abstracts which present cutting edge research that could majorly alter understanding and treatment of the microbiome. The second abstract introduced the findings that support the concept of an individualized microbiome, meaning gut bacteria varies by individual. This research suggests a complex interplay of host-specific factors that play a role in microbiome diversity. The third abstract defied the narrative on Ivermectin, showing that Ivermectin has a role on the microbiome short-term. Which could benefit investigators using it for various therapeutic interventions. Hazan believes that in this growing industry, ProgenaBiome's authentic microbiome research is the "key to science," even if met with controversy. Hazan noticed a growing number of articles have been retracted in the last four years. "This goes against the essence of science. Science is about controversy and defying the narrative. Science is about 'prove me wrong.' Retraction of research should never occur for this reason," said Hazan. The fourth abstract ProgenaBiome submitted describes "significant microbiome changes" in patients suffering from Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) following treatment with Bovine IgG. These findings suggest that Bovine IgG may influence essential gut bacteria – specifically Alisteps, Bacteroides, Bifidobacteria, Actinobacteria, Bacteroidetes and Proteobacteria – to help manage IBS and IBD symptoms. These abstracts are the result of ProgenaBiome's community of specialized physicians who explore topics that others in the medical community see as too daunting or controversial to study. "We do the research nobody wants to do because of expense and controversial nature, but it is research everyone wants to know. Anything short of challenging the narrative is not science – it's propaganda," said Hazan. ProgenaBiome is a standalone research company that is not backed by a large pharmaceutical corporation, but it is interested in guiding the pharmaceutical industry towards this new frontier of research. Their research is funded by individual donations and proceeds from sales products "Lets Talk Sh!T" book and Biomeboosters. "We cannot do this without support from our community, so please consider donating before the end of the year to the Microbiome Research Foundation ," said Hazan. Read more about ProgenaBiome's research, mission, and register to the newsletter through their webpage, progenabiome.com. For more timely information, follow Dr. Hazan on X @SabinehazanMD and Instagram @dr.sabinehazan. For more, visit: Media Contact: 800-380-7764 [email protected] Author: Jamie Miller [email protected] 404-422-9433 SOURCE ProgenaBiome

As part of the Phastar Cares scheme, MDGH has pro bono access to the company’s biometrics experts as it conducts two large double-blind phase 3b clinical studies at sites in the Democratic Republic of Congo and Cote d’Ivoire. One trial is evaluating the safety of moxidectin and the second is evaluating repeat single dosing compared with ivermectin in individuals living in onchocerciasis (river blindness) endemic areas. Graham Clark, CEO at Phastar, said: “We have the expertise and the resources to make a meaningful difference and to deliver on our mission to improve human health. As a B Corp ​organization, we strive to be a force for good ​, and one of our strategic objectives is to lead the CRO industry in corporate social responsibility ​. “The Phastar Cares Scheme, which offers free access to our statisticians, data scientists, data managers, and programmers, is an important part of that commitment. We are proud to be in a position to help MDGH on their mission to eradicate onchocerciasis.” Onchocerciasis is currently controlled through annual or biannual preventive community-directed treatment. Moxidectin has been shown to be significantly superior to the current treatment in phase 2 and phase 3 efficacy clinical trials, with both medicines having similar safety profiles. Impact of moxidectin ​ The impact of moxidectin on onchocerciasis transmission elimination has been extensively studied in mathematical models and the data suggests annual or biannual administration of moxidectin, as an alternative to the current standard of care, could significantly accelerate transmission elimination. googletag.cmd.push(function () { googletag.display('text-ad1'); }); MDGH received FDA approval for moxidectin ​ in 2018 as a single 8mg dose for the treatment of onchocerciasis in people 12 years of age and older with efforts underway to expand the indication to children as young as 4 years. The current double-blind phase 3b study of more than 12,000 participants is an important step in progressing moxidectin for onchocerciasis to achieve World Health Organization guideline inclusion. Once recruitment was completed, a substantial review of the statistical analysis plan along with associated documents for data management, was needed. Phastar’s biostatistics experts, through the Phastar Cares pro bono scheme, reviewed the statistical analysis plan against the protocol's primary and secondary objectives and developed and drafted planned outputs to ensure they meet the stated objectives of the protocol and MDGH’s objectives. Medicines for neglected diseases Mark Sullivan, founder and managing director of MDGH, said: “Developing medicines for neglected diseases for disadvantaged communities is an expensive and complicated process. The support of the Phastar Cares scheme is such a wonderful way for us to access Phastar’s expertise and we greatly appreciate their extraordinarily generous and helpful contribution. “More than 200 million people live in areas of Africa which are endemic for onchocerciasis, a serious, debilitating and stigmatizing neglected infectious disease. Moxidectin is the first new medicine registered for the treatment of onchocerciasis in more than 20 years. The data resulting from MDGH’s current study is critical to enabling the World Health Organization (WHO) to decide on moxidectin’s role in the treatment guidelines on which many countries rely.” Phastar Cares ​ is a pro bono scheme allowing charities to access Phastar’s biometrics experts at no cost.